Etonogestrel And Ethinyl Estradiol Vaginal Ring
Product Images NDC 42291-478

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Etonogestrel And Ethinyl Estradiol Vaginal (NDC 42291-478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3 (478 03)

Packaging label for Etonogestrel and Ethinyl Estradiol Vaginal Ring delivering 0.120 mg/0.015 mg per day. The label indicates the product contains 3 vaginal rings and is for vaginal use. It is labeled for prescription use only and distributed by AvKARE. Storage instructions specify refrigeration at 2-8°C (36-46°F). The label includes warnings and disposal instructions along with barcodes and manufacturer details.*

FDA Label Image

1 (Insertion Image)

An illustration showing three different body positions of a person for vaginal insertion. Figure A shows the person lying on their back with legs bent, Figure B shows the person squatting, and Figure C shows the person standing with one foot raised on a step or chair.*

FDA Label Image

Structure (Enilloring Chemical Structure)

Chemical structures of Etonogestrel and Ethinyl Estradiol shown with their molecular formulas C22H28O2 and C20H24O2 respectively. The illustrations depict the steroid backbone and functional groups characteristic of these active ingredients.*

FDA Label Image

Image Description (Enilloring Figure 1)

A horizontal bar graph showing the number of women with a blood clot out of 10,000 woman-years for different groups: Non-CHC user non-pregnant, CHC user, pregnant, and postpartum (12 weeks only). The chart displays risk ranges, with postpartum women having the highest range (40 to 65) and non-CHC non-pregnant users the lowest (1 to 5).*

FDA Label Image

Enilloring-chart (Enilloring Figure 2)

A forest plot chart showing effect estimates comparing ever and current use of combined oral contraceptives (COC) versus never use. The chart lists various studies from 2002 to 2017 on the left, plots effect estimates with confidence intervals against a central line of 1.00 along the x-axis labeled 'Effect Estimate,' and displays odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals on the right.*

FDA Label Image

Image Description (Enilloring Figure 3)

A line graph showing serum concentrations over 21 days after insertion of Etonogestrel and Ethinyl Estradiol Vaginal Ring. Etonogestrel levels (pg/mL) rapidly increase to around 1500 pg/mL then plateau, while Ethinyl Estradiol (EE) levels remain steady around 400-500 pg/mL throughout the period. The x-axis represents days after ring insertion.*

FDA Label Image

Fig-1b (Enilloring Figure 4)

A vertical arrow diagram illustrating pregnancy rates per 100 women in one year, arranged from fewer to more pregnancies. The diagram categorizes birth control methods into groups: implants, injections, intrauterine devices, sterilization at the top with fewer pregnancies; birth control pills, skin patch, vaginal ring with hormones next; condoms and diaphragm in the middle; no sex during fertile days, spermicide, and withdrawal below that; and no birth control at the bottom with the highest pregnancy rate.*

FDA Label Image

Enilloring-barchart 2 (Enilloring Figure 5)

A horizontal bar chart depicting the number of women with a blood clot per 10,000 woman-years (WYY) for four groups: Non-CHC user, Non-Pregnant; CHC user; Pregnancy; and Postpartum (12 weeks only). The chart shows increasing ranges from 1-5 for Non-CHC users to 40-65 for Postpartum women.*

FDA Label Image

Image Description (Enilloring Figure 7)

Illustrated instructional figures showing a hand holding a vaginal ring. Figure D depicts the ring being grasped between thumb and index finger. Figure E shows the hand pinching and slightly compressing the ring between thumb and index finger, likely demonstrating insertion or handling technique for Etonogestrel and Ethinyl Estradiol Vaginal Ring.*

FDA Label Image

Image Description (Enilloring Figure 8)

An instructional diagram showing the method of vaginal insertion for Etonogestrel and Ethinyl Estradiol Vaginal Ring. It depicts a hand placing the ring inside the vaginal canal within a cross-sectional view of female pelvic anatomy.*

FDA Label Image

Image Description (Enilloring Figure 9)

Illustrations showing vaginal insertion and positioning of the Etonogestrel and Ethinyl Estradiol Vaginal ring (EnilloRing). Figures depict the ring being placed into the vagina with labeled anatomy including uterus and vagina, demonstrating the ring's placement inside the vaginal canal near the cervix.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.